Lippincott’s client, one of the world’s most prolific biotechnology firms, has been a healthcare powerhouse fueled by unprecedented medical innovation, excellence in sales and marketing, and an extraordinary commitment to building a progressive culture. The company has delivered dozens of life-changing medical breakthroughs in the past 20 years.
Like many of the most successful companies, they have benefited from a consistent partnership in negotiating their way through seismic industry changes: The Affordable Care Act that rewrote the definition of therapeutic value and turned pricing models upside down; the financial collapse of 2008 and its formidable economic headwinds; even the rise of generics and the loss of exclusivity for key drugs.
On top of all these, new molecule discovery has slowed across the industry, requiring drug companies to find innovative ways to extract more value from the molecules they have in their pipelines. Throughout all of the obstacles in the company’s path over the past two decades, Lippincott has been a key partner in building and sustaining the company’s capability to grow and impact the world of health.
The discipline to integrate change in every facet of the organization
From the outset, Lippincott has focused on identifying and implementing the leadership, management, communications, talent, process and systems changes needed to fuel transformation.
Working with every function, from Early Development to Sales and Marketing, IT, Site Services, Legal, HR, Medical Affairs and Regulatory Affairs, we’ve helped the company navigate and stay ahead of the profound changes that have repeatedly redefined the healthcare landscape — even the impact of one of the healthcare industry’s largest-ever mergers, out of which the company emerged stronger than ever.
Throughout, Lippincott has been on hand to help senior leaders and their teams rapidly recalibrate their ambitions and strategies to accommodate ever-changing realities on the ground. Our facilitated, carefully designed and participative workshops, of which we’ve conducted hundreds at the biotech company over the years, have proven to be the ideal way to achieve team alignment, rapid decision-making and robust strategic planning.
Lippincott has diagnosed decision-making bottlenecks at every level and engaged senior leaders in the task of clarifying expectations and decision rights. We’ve fostered a culture of speaking up, so vital for creativity and innovation, by taking hundreds of leaders through an interactive, somatic workshop.
Our creative engagement programs have consistently connected employees with the company’s patient-centric purpose, even when the task at hand has been to drive greater compliance or realize operational savings.
We’ve prepared multiple commercial organizations for pending FDA decisions in the fields of immunology, oncology and cardiovascular health — giving them the flexibility to accelerate on approval, or accept failures with a productive, future-oriented mind-set.
With participation always front and center, we crowdsourced the company’s post-acquisition narrative, inviting employees to look forward rather than back by asking them what they could do now that they couldn’t do before and to reflect on the characteristics that define the company at its best.
We’ve advised the biotech powerhouse on the concept for its campus of the future, creating a socially connected hub for thousands of employees, and increased participation in its in-house transportation network by highlighting the resources employees would free up for patients if they used shared commuting services.
We’ve worked with HR leaders to define its talent vision and value proposition, and we’ve fostered more collaborative partnerships that keep business leaders aligned in their approach to hiring and mobility.
Most recently, we’ve transformed a group that helps uninsured and underinsured patients start and stay on therapy — building a culture in which employees feel connected to their patient impact, partner seamlessly across teams and invest in their career development.
A partnership rooted in results
- More than 15 straight years on Fortune magazine’s “Best Companies to Work For” list
- More than 200 percent employee growth over 10 years
- More than 30 drugs in market
- Double-digit growth in more than a dozen employee engagement metrics in the past six months
- 7,000 employee responses in narrative crowdsourcing
As the accomplishments listed above show, these efforts have paid off abundantly. Its reputation as the home of the best and brightest in biotechnology is as strong as ever. Most important, the company continues to deliver historic medical breakthroughs and treatments while innovating new patient and provider experiences each and every day.